Moleculin Biotech
MBRX
9 hedge funds and large institutions have $1.53M invested in Moleculin Biotech in 2024 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 8 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
5.8% less ownership
Funds ownership: 17.39% → 11.59% (-5.8%)
40% less funds holding
Funds holding: 15 → 9 (-6)
75% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 8
96% less capital inflows, than outflows
Capital inflows: $38.4K | Capital outflows: $881K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$29.8K |
| 2 |
FIM
FWL Investment Management
Dallas,
Texas
|
+$4.26K |
| 3 |
Newbridge Financial Services Group
Boca Raton,
Florida
|
+$4.26K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Armistice Capital
New York
|
-$559K |
| 2 |
Renaissance Technologies
New York
|
-$111K |
| 3 |
State Street
Boston,
Massachusetts
|
-$61.3K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$55.5K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$46K |
MBRX Hedge Fund Activity: Q1 2024 in Review
9 of the 6,966 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q1 2024, worth a combined $1.53M — down 66% from $4.44M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of MBRX and 2 opened new positions — a net loss of 6 holders — while 1 trimmed existing stakes and 1 added.
The largest buyer was Vanguard Group, adding an estimated $29.8K. The largest seller was Armistice Capital, cutting an estimated $559K.
- 9 institutional investors held Moleculin Biotech (MBRX) as of Q1 2024, down from 15 in Q4 2023.
- Funds reported $1.53M of Moleculin Biotech stock for Q1 2024, down 66% quarter-over-quarter.
- 2 funds opened new Moleculin Biotech positions in Q1 2024 and 8 closed out, a net change of -6 holders.
- The largest Moleculin Biotech buyer in Q1 2024 was Vanguard Group, an estimated $29.8K added.
- The largest Moleculin Biotech seller in Q1 2024 was Armistice Capital, an estimated $559K sold.
Based on aggregated 13F filings for Q1 2024.